Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling

Sep. 01, 2022 4:19 PM ETIntellia Therapeutics, Inc. (NTLA)By: Anuron Mitra, SA News Editor2 Comments

alphabet letters spelling angioedema

Sopone Nawoot

  • Intellia Therapeutics (NASDAQ:NTLA) on Thursday said the U.S. FDA had granted an orphan drug designation to the company's genome editing candidate NTLA-2002 for the treatment of hereditary angioedema (HAE), a disorder characterized by recurring episodes of severe swelling.
  • The FDA's orphan drug designation program expedites the development and evaluation of a drug or biological product to prevent a rare disease or condition.
  • Intellia (NTLA) said its NTLA-2002 investigational therapy is designed to target the KLKB1 gene to reduce plasma kallikrein activity and thus prevent HAE attacks.
  • The therapy is currently being evaluated in an early-to-mid stage trial in adults with type I or II HAE.
  • The company expects to present interim data on NTLA-2002 at a symposium later this month.
  • NTLA stock earlier closed -0.2% at $59.97.

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.